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Abstract
A Fab-like antibody binding unit, ccFv, in which a pair of heterodimeric coiled-coil domains was fused to VH and VL for Fv
stabilization, was constructed for an anti-VEGF antibody. The anti-VEGF ccFv showed the same binding affinity as scFv but
significantly improved stability and phage display level. Furthermore, phage display libraries in the ccFv format were
constructed for humanization and affinity maturation of the anti-VEGF antibody. A panel of VH frameworks and VH-CDR3
variants, with a significant improvement in affinity and expressibility in both E. coli and yeast systems, was isolated from the
ccFv phage libraries. These results demonstrate the potential application of the ccFv antibody format in antibody engineering.
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Introduction
The field of therapeutic antibody development has exploded in
the past two decades with the invention of various antibody
formats [1,2]. These novel antibody fragment formats are possible
because antigen recognition occurs through a discrete region of
the molecule known as the Fv fragment. Comprised of two
variable regions, the heavy and light chains (VH and VL,
respectively), the Fv fragment contains all the structural informa-
tion necessary for high affinity antigen binding.
Although the Fv fragment can recognize an antigen, the
interaction energy between the VH and VL chains is low. Thus,
Fvs are often too unstable for therapeutic applications. In naturally
occurring immunoglobulins (Igs), the VH and VL regions are held
together by the CH1 and CL domains as well as by an interchain
disulfide bond. These four regions, together with the interchain
disulfide bond, comprise a Fab. In contrast to the smaller Fv
fragment, Fabs are much more stable, making them more broadly
applicable not only to research but also to immunodiagnostic and
immunotherapeutic applications; however, this stability results
from a relatively high molecular weight of 50 kDa.
The ideal antibody fragment would have three properties: small
size, high binding affinity (nanomolar or below), and high stability,
including the ability to withstand physiological salt, pH and
temperature conditions. In light of these requirements, a variety of
approaches have been taken to build a functional, stable complex
of VH and VL. The commonly used single chain Fv, or ‘‘scFv,’’
approach utilizes a flexible peptide linker to covalently connect the
VH and VL domains into a single polypeptide [3,4]. The resulting
scFv exhibits substantial antigen-binding activity compared to a
non-disulfide-bonded Fv fragment. However, scFvs tend to form
dimers and aggregates [5,6] and are relatively unstable compared
to Fabs [7]. scFv molecules need to be further engineered to
improve their stability for many therapeutic applications.
We and others have created Fab-like molecules (hsFv and ccFv)
by replacing the CH1a n dC L domains with smaller heterodimeric
domains. The hsFv complex utilized two engineered helical
domains from Fos and Jun to dimerize the VH and VL domains
from an anti-phosphorylcholine antibody, yielding a helix-stabilized
Fv fragment [8]. In the ccFv construct, the VH and VL domains
were dimerized via a pair of naturally occurring coiled-coil domains
derived from the heterodimeric GABAB receptors [9]. These Fab-
like formats confer the desired advantages of relatively small size
(approximately 35 to 37 kDa) and high stability and affinity.
Here, we report the characterization of an anti-VEGF ccFv
antibody. Our data showed that the ccFv molecule had a binding
affinity similar to the corresponding scFv but was significantly
improved in thermostability and phage display level. Furthermore,
ccFv phage display libraries were constructed for humanization
and affinity maturation of the anti-VEGF antibody. A panel of VH
frameworks and VH-CDR3 variants with significant improvements
in affinity and expressibility were isolated by library panning. This
study demonstrates the utility of the ccFv format in antibody
engineering and its feasibility for diagnostic and immunothera-
peutic applications.
Results
ccFv construct
To construct a Fab-like molecule (Figure 1A), it was necessary to
select an optimal pair of heterodimerization domains to fuse with
VH and VL. Based on several desirable features, we chose the
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from the GABAB-R1 and GABAB-R2 receptors. A previous study
has demonstrated that the GR1 and GR2 peptides preferentially
form parallel coiled-coil heterodimers under physiological buffer
and temperature conditions. The GR1 coiled-coil peptides folded
into relatively unstable homodimers, whereas the GR2 coiled-coil
peptides were largely unstructured and could not form homodi-
mers [10].
To provide additional flexibility for the heterodimerization of
VH and VL, we modified the amino termini of GR1 and GR2 by
adding a 6-amino-acid flexon (Ser-Arg-Gly-Gly-Gly-Gly). To
further stabilize the ccFv construct, a pair of cysteine residues
was added via a spacer (Val-Gly-Gly-Cys) at the C-termini of the
GR1 and GR2 domains. These domains are, in turn, fused to the
carboxyl termini of the VH and VL fragments, respectively. The
sequences of GR1 and GR2 with the above modifications are
listed in Figure 1B. Because the antibody VH and VL domains are
heterodimerized through the coiled-coil domains, the new format
is named a coiled-coil Fv or ‘‘ccFv’’.
ccFv expression and stability
The VH and VL sequences of a humanized anti-VEGF antibody
[11] were selected and converted to anti-VEGF ccFv and scFv (a
control). To characterize the newly created ccFv, the anti-VEGF
ccFv and scFv were first cloned into a bacterial vector for
expression. However, both ccFv and scFv had a low expression
yield (below 20 mg/L). Therefore, we switched to a Pichia system to
express the anti-VEGF ccFv and scFv antibodies; the expression
vector for ccFv is shown in Figure 1D. The Pichia system
significantly improved the expression yield. A total of 50 ml
induced culture generated approximately 0.5 to 1 mg of purified
ccFv and scFv antibody proteins, which were enough for further
characterization.
The Pichia-expressed soluble anti-VEGF ccFv and scFv
antibody fragments were subsequently purified with a Ni-NTA
column via their histidine tags. Figure 2A shows that the purified
ccFv has an electrophoretic mobility of approximately 35 kDa on
a non-reducing gel. Under reducing conditions, two subunits
corresponding to VL and VH were observed. Western blotting with
an anti-Myc-tag antibody confirmed the identity of the upper
band as the VL-Myc-His-tag fusion protein (data not shown).
Furthermore, the Biacore measurement showed that the ccFv
bound to the VEGF antigen with 10.3 nM affinity, which was
similar to that of scFv (13.8 nM). These results demonstrated that
the ccFv molecule could be successfully expressed and functionally
assembled in Pichia cells.
The stability of the anti-VEGF ccFv was compared to that of its
corresponding scFv antibody. The bindings of the antibodies to
VEGF were measured at 25uC after a 16 h incubation at either
4uC, 37uCo r4 2 uC. Their remaining ability to bind to the antigen
Figure 1. An overview of the coiled-coil Fv (ccFv) construct. (A) The ccFv molecule design. The VH and VL are heterodimerized through the
interaction of GR1 and GR2 coiled-coil domains. (B) The amino acid sequences of GR1, GR2, linker, and spacer. (C) pABMD5, the ccFv phage display
vector. (D) pABMX168, the ccFv expression vector in Pichia.
doi:10.1371/journal.pone.0019023.g001
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exhibited significantly higher stability than the scFv antibody,
with 90% and 44% of antigen binding activities remaining after
37uC and 42uC overnight incubations, respectively, whereas only
22% and 3% of the antigen binding activity of the scFv remained
after the same treatments.
Taken together, these results indicate that the novel antibody
fragment construct ccFv showed affinity and expressibility
comparable to scFv and better stability than scFv.
Use of ccFv in phage display
To demonstrate the utility of ccFv in a phage display system, we
constructed a phagemid vector by subcloning the anti-VEGF-ccFv
gene into the pABMD5 vector (Figure 1C). To compare the ccFv to
the scFv in phage display, phagemids encoding both the ccFv and
scFv anti-VEGF fragments were prepared. As shown in Figure 3A,
phages displaying either the ccFv or scFv bound specifically to the
antigen VEGF in a dose-dependent manner. The positive ELISA
signal indicated the successful assembly and expression of the
functional ccFv fragments on phages. Moreover, the phages
displaying the ccFv fragments exceeded those displaying the scFv
by almost one order of magnitude in binding.
To verify the display levels, the same amounts of phage particles
displaying either ccFv or scFv were subjected to SDS-PAGE and
anti-HA-tag western blotting. As shown in Figure 3B, more intact
ccFv-pIII fusion proteins were observed than the intact scFv-pIII,
suggesting a higher ccFv display level, which was consistent with
the ELISA results.
To demonstrate that a specific ccFv phage could be selected
from a ccFv phage display library, we constructed a ‘‘doped
library’’ and panned for specific binders. Phages displaying an
anti-VEGF ccFv fragment were mixed with control phages
displaying ccFv fragments that do not bind to VEGF in a ratio
of 1:10
7. A total of 10
12 phages were used in two rounds of
panning against immobilized VEGF. After each round of panning,
the bound library phages were harvested and tested for antigen
recognition in an ELISA against immobilized VEGF. Simulta-
neously, to monitor the actual enrichment of the panning, the ratio
of the anti-VEGF phage to the background phages was measured.
Randomly picked clones were analyzed by PCR via a pair of
primers specifically designed to amplify only the anti-VEGF ccFv
and generate a band of approximately 1 kb. The phages from the
second round generated an ELISA signal of OD405 3.8,
significantly higher than the signal of OD405 0.05 from the first
round, demonstrating that the anti-VEGF-ccFv-displaying phages
could be successfully selected by panning. PCR analysis confirmed
the enrichment of the anti-VEGF ccFv. Although the original
1:10
7 doped library contained only 0.00001% anti-VEGF ccFv, its
presence increased to 4% (2/25) after a single round of panning
and reached nearly 100% (14/14) after the second round.
Application of ccFv in antibody humanization
To examine the utility of the ccFv format in antibody
engineering, a VH library was constructed in the ccFv format to
humanize a murine anti-VEGF antibody [12]. This library, with a
diversity of 1.6610
6, was designed based on VH structure modeling
and the human germline sequence. The ccFv library phages were
used to select against human VEGF. After 8 rounds of panning,
three dominant hits, X72, X76, and X78, were identified. X72
represented 50% of the ELISA-positive clones, X76 25%, and X78
Figure 2. The expression of the ccFv fragment in Pichia and the study of its stability. (A) SDS-PAGE analysis of purified ccFv and scFv, under
reducing (b-ME) and non-reducing conditions. ccFv showed an electrophoretic mobility of approximately 35 kDa. Under reducing conditions, two
ccFv subunits corresponding to VL-GR2-Myc-His tag and VH-GR1 were observed. (B) A thermal stability comparison between ccFv and the
corresponding scFv. The anti-VEGF ccFv and scFv fragments were incubated at 4uC (referred to as 100% binding activity), 37uC, and 42uC. Their
remaining binding activity to the VEGF antigen was measured by Biacore at 25uC.
doi:10.1371/journal.pone.0019023.g002
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Figure 4. Phylogenic analysis indicates that these VH frameworks
are undistinguishable from human germline families.
Compared to the previously humanized antibody VH sequence
(referred to as WT) [11], different framework residues were
identified in all three hits. The E6Q and L11V changes in FR1
were shared by all three hits. X76 also differed from the WT at
one position in FR2 and at two positions in FR3, whereas X78
differed at two more positions in FR1 and one position in FR3
(Fig. 4).
The expressibility and affinity of the three hits were further
characterized. To exclude any potential bias from the new ccFv
format, the hits and the WT were converted to the established
scFv format for Pichia expression. The his-tagged scFv fragments
were purified by a Ni-NTA column from methanol-induced
culture supernatants and analyzed by SDS-PAGE. As shown in
Fig. 5A, the expression levels of X72, X76, and X78 were
significantly higher than that of the WT X50. With experimental
variation from batch to batch, the expression yields of all three hits
were 5- to 10-fold higher than that of the WT. In addition, Biacore
measurements indicated that the affinities of the new hits increased
2.3- to 4.5-fold relative to the WT (Table 1).
Application of ccFv in antibody affinity maturation
To improve the affinity of the anti-VEGF antibody, two
combinatorial CDR3 libraries in the ccFv format, Libraries 1 and
Figure 3. The functional phage display of the ccFv fragment. (A) Phage ELISA was conducted using the phages displaying either the ccFv or
scFv fragment encoding the same anti-VEGF antibody. The results demonstrated that ccFv was functionally assembled, expressed, and displayed on
phages. The display level was higher by almost one order of magnitude than scFv. (B) A western blot of phages displaying ccFv and scFv fragments.
The same amounts of phage particles displaying either the ccFv or scFv fragment were analyzed by SDS-PAGE and anti-HA western blotting. More
intact ccFv-pIII fusion proteins were detected than the intact scFv-pIII fusion proteins, suggesting a higher ccFv phage display level.
doi:10.1371/journal.pone.0019023.g003
Figure 4. The framework amino acid sequences of the leads selected from the ccFv humanization library for the anti-VEGF
antibody. All three leads, X72, X76, and X78, differed from WT at the E6Q and L11V mutations in the VH framework 1. The Kabat numbering scheme
was used for residue numbering.
doi:10.1371/journal.pone.0019023.g004
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separately panned against immobilized VEGF. After multiple
rounds of panning, 92 clones were randomly picked from each
library and examined by phage ELISA. All clones demonstrated
positive binding activity to VEGF.
Library 1 had diversity at positions 95, 97, 99 to 100c and 102.
After 5 rounds of panning, the mutations at positions 97 and 100a
were identified. All positive clones carried the 97 histidine (H) to
tyrosine (Y) change, and 80% of clones had a serine (S) to
threonine (T) mutation at position 100a. From Library 2, with
diversity at positions 94 to 96, 100a to 100d, and 102, after 7
rounds of panning, 70% of clones had the change from 100a
serine (S) to arginine (R), whereas 30% had the serine (S) to
threonine (T) change that was dominant in the Library 1 selection.
These mutations have also been reported in a previous study [13].
Three clones, X63 (with the mutations H97Y and S100aT),
X64 (with the mutation S100aR), and X65 (with the mutations
H97Y and S100aR), were converted to scFv formats and
expressed in Pichia. Their affinities were measured by Biacore
and showed 2.5- to 9.2-fold improvement than the WT (Table 1).
Next, the VH-CDR3 mutants in X65 were grafted into X72 and
X76 frameworks, resulting in two constructs, X96 and X97,
respectively. The scFv formats of these two variants were then
expressed in Pichia to examine their expressibility. As shown in
Figure 5B, both constructs maintained the good expressibility
inherited from the X72 and X76 frameworks. Their affinities were
determined by Biacore analysis at the elevated temperature of
35uC due to the slow dissociation rate at 25uC. The results in
Table 2 show that both X96 and X97 exhibited a greater than 30-
fold improvement in VEGF binding affinity.
Furthermore, the expressibility of the improved clones X96 and
X97 in the Fab format was examined in E. coli. The Fabs were
expressed in TG1 cells and purified from periplasm by protein G
columns. Consistent with the improvement in Pichia, a significant
improvement in Fab expression in E. coli was observed as well. The
purification yields of the X96 and X97 Fabs reached 229 and
303 mg per liter in TG1 culture, respectively, approximately 10-
and 15-fold higher than that of the WT Fab, which was 21 mg/L.
Discussion
The coiled-coil leucine zipper domains have been used to
reconstitute a variety of heterodimeric complexes [14]. With the
Figure 5. Improved expression of the leads identified from the ccFv humanization and maturation libraries for an anti-VEGF
antibody. The leads identified from the ccFv libraries were converted to scFv and expressed in Pichia. (A) SDS-PAGE analysis of the expression of the
humanization leads (X72, X76, and X78) and the WT control. All three leads showed an expression level significantly higher than that of WT X50. (B)
SDS-PAGE analysis of the expression of X96 and X97, which carried the combined mutations identified from both the humanization and the
maturation libraries.
doi:10.1371/journal.pone.0019023.g005
Table 1. Affinity of variants post humanization or maturation
at 25uC.
Hit kon610
3 koff610
24 Kd (nM) Kd
WT/Kd
Hit
WT 6.1460.04 0.8560.01 13.8 1
X72 17.960.13 0.6960.05 3.9 3.5
X76 37.460.50 1.1560.01 3.1 4.5
X78 12.260.09 0.7260.05 5.9 2.3
X63 1.1460.06 0.02560.02 2.2 6.3
X64 15.960.09 0.86760.03 5.4 2.5
X65 2.2560.04 0.03460.01 1.5 9.2
doi:10.1371/journal.pone.0019023.t001
Table 2. Affinity of VH variants at 35uC.
Hit kon610
4 koff610
24 Kd (nM) Kd
WT/Kd
Hit
WT 7.660.03 2.9060.01 3.8 1
X96 8.560.04 0.0960.01 0.11 35
X97 11.560.1 0.1460.03 0.12 31
doi:10.1371/journal.pone.0019023.t002
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into the mechanism of helix formation, several groups have
pursued library approaches to engineer interacting domains that
might best induce heterodimer assembly [15,16]. In such libraries,
the key positions of the helical structure were partially randomized
and the best interacting partners were selected through ‘‘library
against library’’ screening. Both engineered and naturally
occurring coiled-coil domains have been utilized in the efforts to
construct the smaller Fab-like molecules [8,9].
WinZip-A2B1, an engineered heterodimeric coiled-coil pair,
was selected simultaneously from two libraries using an in vivo
protein-fragment complementation assay with dihydrofolate
reductase [16]. This selected peptide pair greatly favored
heterodimerization over homodimerization. However, similar to
the parental Jun/Fos leucine zipper pair, both WinZip-A1 and
WinZip-B1 can form homodimers, whereas the homodimeric
WinZip-A1 is almost as stable as the heterodimer. Because this
leucine zipper pair was overwhelmingly selected using E. coli,i t
was assumed that the helical domains were metabolically stable
and functionally active in such system. The WinZip-A2B1 coiled-
coil domains were used to heterodimerize the VH and VL of an
anti-phosphorylcholine antibody, creating the helix-stabilized Fv
fragment hsFv [8]. In contrast to the scFv format, which is prone
to aggregation, the hsFv format showed higher stability and no
tendency to oligomerize or aggregate. The hsFv also boasts a
relatively small size of 37 kDa.
In this study, we designed a functional antibody fragment
format, the ccFv, by inducing the dimerization of a pair of
naturally occurring, intracellular coiled-coil domains. Fos and Jun,
the well-characterized coiled-coil leucine zipper proteins, can
heterodimerize but are prone to homodimerization as well [17]. In
contrast, the C-terminal coiled-coil domains (GR1 and GR2) of
the GABAB-R1 and GABAB-R2 receptors do not form detectable
homodimers either in vivo or in vitro. Previous studies have
demonstrated the heterodimerization specificity of GR1 and
GR2 in vivo [18,19]. In fact, White et al. [19] have been able to
clone GR2 from a yeast two-hybrid system based on the exclusive
specificity of this heterodimeric receptor pair. In vitro studies by
Kammerer et al. [10] have shown that neither GABAB-R1 nor
GABAB-R2 C-terminal sequence can form homodimers in
physiological buffer conditions at physiological body temperatures.
The current study demonstrated that the GR1 and GR2 coiled-
coil domains effectively stabilize VH and VL in the construction of
a coiled-coil Fv domain, or ‘‘ccFv’’.The ccFv molecule has a
shorter linker of six amino acids between the antibody variable
sequences and the coiled-coil domains compared to the 13 amino
acid-linker in hsFv. By using a linker of only 6 amino acids, we
constructed multiple functional ccFv antibodies (data not shown),
suggesting that shorter linkers worked well. Additionally, a
covalent interchain bond was engineered at the C-termini of the
GR1 and GR2 domains to further stabilize the ccFv construct.
The ccFv antibody format was based upon previous efforts to
construct a small antibody fragment that could remain stable
under physiological conditions. Because of their small sizes, ccFv
and its derivatives are potentially more useful than traditional
antibodies for clinical applications requiring tumor and tissue
penetration.
A main effort in current antibody engineering involves the use
of phage display library construction and panning to select high
affinity antibodies for research and therapeutic purposes [20,21].
Panning of first a ‘‘doped’’ library and then the optimized libraries
revealed that high-affinity, high-specificity binders can be selected
using the ccFv format. In addition to the affinity improvement, we
identified three humanized VH frameworks that significantly
improved the production of the anti-VEGF antibody in both the
scFv and Fab formats. Compared to the previous humanized
sequence, all three new hits shared two key mutations of E6Q and
L11V in the VH framework 1. Recent studies have suggested that
the VH framework residue at position 6 plays a critical role in
antibody folding, antigen-binding activity, and determination of
the local conformation of the framework 1 region [22,23,24].
From a structural point of view, the burial of a charged glutamate
(E) residue at position 6 would be energetically unstable. It has
been reported in a bacterial system that the substitution of
glutamate (E) with glutamine (Q) at position 6 dramatically
improved (by 30-fold) the scFv production for an anti-CD3
antibody [25]. Our data showed that the exchanges of E6Q and
L11V significantly improved the expression not only in the
prokaryotic E. coli system but also in the eukaryotic yeast (Pichia)
system. The influence of the L11V exchange remains to be
determined. Structure modeling and analysis suggested that this
L11V change would be energetically favorable (data not shown).
In summary, this study demonstrated the utility of the GR1 and
GR2 coiled-coil domains in reconstituting the characterized Fv
fragment; the resulting coiled-coil Fv antibody fragments (ccFvs)
can be effectively used in constructing large libraries and selecting
novel antibodies via phage display.
Materials and Methods
Materials
Escherichia coli TG1 cells [supE thi-1 D (lac-proAB) D (mcrB-hsdSM)5
(rK
2 mK
2) [F’ traD36 proAB lacI
qZDM15] were used for the
production of plasmid DNA and phages; the KO7 helper phage
and HRP-conjugated anti-M13 antibody were from Amersham
Pharmacia Biotech; pBluescript SK(+) was from Stratagene; the
Pichia pastoris expression system, including the pPIC6 alpha vector
and X33 train, was from Invitrogen.
Recombinant VEGF121 was from Calbiochem; the HRP
substrate ABTS [2,29 Azino-bis(3-ethylbenzthiazoline-6-sulfonic
acid)] and triethylamine were from Sigma; Maxisorb 96-well plates
were from Nalgene-Nunc.
Vector construction
The vectors for antibody expression and display in TG1 cells
were derived from pBluescript SK(+). A unique AgeI restriction
site was introduced immediately after the 39 of the lac promoter by
PCR-based site-directed mutagenesis with a set of primers (pBS-
SKa: 59-GGAATTGTGAGCGGATAACAATTTACCGGTCA-
CACAGGAAACAGCTATGAC CATG-39 and pBS-SKb: 59CA-
TGGTCATAGCTGTTTCCTGTGTGACCGGTAAATTGT-
TATCCGCTCACAATTCC-39); the XhoI and KpnI sites were
then deleted by restriction digestion and blunt end ligation. For
ccFv expression, the synthetic DNA fragment flanked by an AgeI
site at the 59 end and BglII/EcoRI sites at the 39 end and
containing ribosome binding sequence-fd phage gene8 leader
sequence-VH-GR1 coding sequences and ribosome binding
sequence-fd phage gene3 leader sequence-VL-GR2 coding
sequence-HA/His tag sequences was cloned into the modified
pBluescript SK(+). The resulting vector was designated pABMX5.
To display ccFv, a PCR-amplified fd gene3 fragment flanked by
BglII and SalI sites was inserted into vector pABMX5 to make the
phagemid display vector pABMD5 (see Figure 1C). The VH and
VL genes of anti-VEGF antibodies A4.6.1 and Fab-12 [11] were
obtained by PCR assembly of overlapping oligonucleotides, and
the sequence was confirmed by DNA sequencing.
To express scFv in Pichia, the scFv gene was cloned into the
Pichia expression vector pPIC6 alpha (Invitrogen) via the XhoI and
ccFv for Antibody Engineering
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The ccFv Pichia expression vector was also derived from the pPIC6
alpha vector. The HindIII site in the 39 end of the AOX1
promoter was eliminated by single nucleotide substitution
(AAGCTT changed to AATCTT) and then inserted after the a-
factor sequence. To construct the anti-VEGF ccFv Pichia vector, a
synthetic fragment containing the VH-GR1 coding sequence-
termination sequence AOX1TT and the AOX1 promoter-VK-
GR2 coding sequence was cloned into the Hind III and Not I sites
of the newly engineered pPIC6 alpha vector; the resulting
construct was in frame with the a-factor and the Myc-His tag
(pABMX168 in Fugure1D).
For Fab expression in E. coli, the VH and VK sequences were
cloned into the modified pABMX492 vector, avoiding the GR1
sequence [26].
Antibody expression and purification
Pichia X33 cells containing either ccFv or scFv constructs were
grown at 30uC in 500 ml BMGY medium (100 mmol/L
potassium phosphate (pH 6.0), 1.34% yeast nitrogen base with
ammonium sulfate, 0.4 mg/L of biotin, 10 g/L yeast extract,
20 g/L peptone, and 1% glycerol)/kanamycin (70 mg/L) until the
OD at 600 nM reached 2.5. The cells were pelleted and
resuspended to a final volume of 50 ml in BMMY medium
(0.5% (v/v) methanol instead of glycerol in BMGY)/kanamycin
(70 mg/L)for a 5-day induction at 30uC. Methanol (0.5 ml) was
added daily to maintain the methanol concentration at 1%. After
methanol induction, the cells were removed by centrifugation, and
the supernatant was subjected to a 1 ml Ni-NTA column (Qiagen).
The bound proteins were eluted with 500 mM imidazole in PBS.
Fractions of 0.5 ml were collected from the beginning of the
elution, and the fractions (number 2 and 3) containing the
antibody protein were combined and dialyzed against PBS.
Twenty microliters of each purified sample was analyzed by
SDS-PAGE.
For bacterial expression of the antibody fragments, TG1 cells
harboring phagemid vectors were grown in 500 ml 2xYT medium
containing 100 mg/ml carbenicillin and 0.1% glucose until the
OD600 reached 0.7. IPTG (1 mM) was added for a 4-h induction
at 30uC. After the periplasmic and osmotic shock preparation of
the TG1 cell pellets, the supernatant was dialyzed against PBS and
subjected to column purification. For the His-tagged scFv and
ccFv, the samples were loaded into a 1-ml Ni-NTA column
(Qiagen). The bound proteins were eluted with 500 mM imidazole
in PBS. For Fab, the samples were loaded onto a 1-ml Protein G
column (GE), and the column-bound Fabs were eluted by pH 3.0
100 mM glycine. The fractions containing antibody proteins were
combined and dialyzed against PBS. Twenty microliters of each
purified sample was analyzed by SDS-PAGE.
Antibody library construction
A humanization library of size 1.6610
6 clones was designed for
the murine anti-VEGF antibody A4.6.1 [12,27], based on
antibody structure modeling and the human germline sequence.
During the operation of humanization in silico [28], 34 positions in
the VH framework were designed: 16 had designed diversity, and
18 were fixed. The library was constructed in the ccFv format. For
affinity maturation, two combinatorial CDR3 libraries in the ccFv
format, Libraries 1 and 2, were constructed in the humanized
framework [11]. Library 1, with a size of 6.6610
5, had diversity at
positions 95, 97, 99 to 100c and 102; Library 2, with a size of
1.7610
5, covered positions 94 to 96, 100a to 100d, and 102.
The humanization and maturation libraries in this study were
constructed by PCR assembly of overlapping oligonucleotides
containing variable nucleotides at key positions to generate
mutations at specific sites. The PCR assembly was performed as
follows: the library oligonucleotides were mixed to a final
concentration of each oligonucleotide of 0.5 mM. Three panels
of assembly reactions were set up with 0.2 mM of each dNTP,
1 mM magnesium sulfate, 5 U of Pfu Turbo DNA polymerase,
and differing amounts of oligonucleotide mix (1 ml, 2 ml, and 3 ml,
respectively) in 1 X Pfu buffer to a total volume of 50 ml. A total of
25 cycles of PCR (94uC 45 sec; 51uC, 45 sec; 72uC, 1 min) were
performed to assemble the overlapping oligonucleotides into
antibody genes. Following assembly, the antibody genes were
amplified by 35 cycles of PCR (same as above) using the assembly
reactions as templates. The PCR-amplified DNA fragments were
then digested and cloned into their corresponding positions in the
ccFv vector.
Phage display and panning
The phagemid vector or library DNA was transformed into TG1
cells. The transformed cells were superinfected with KO7 helper
phage, with a multiplicity of infection (MOI) of 5 to 10. After an
overnight culture at 30uC in 2xYT medium with 100 mg/ml
carbenicillin and 35 mg/ml kanamycin, the phage particles were
purified by two times of PEG precipitation from culture
supernatants and titered by OD268 measurement. The antibody
displayed on the phage surface was detected by phage ELISA using
plates coated with VEGF or by phage western blot.
For phage library panning, recombinant VEGF was immobi-
lized onto Nunc Maxisorb 96-well plates in 0.05 M NaHCO3,
pH 9.6 buffer at 4uC overnight. An aliquot of the phage library
containing 10
12 phage particles diluted in PBS buffer with 2% milk
was added to the wells coated with the antigen. After incubating at
room temperature for 2 h, the wells were washed with PBST
(0.05% Tween-20 in PBS) and PBS. Bound phages were eluted
with 100 mM triethylamine and added to a TG1 culture (grown at
37uC until the OD600 reached approximately 0.5 to 1.0) for
infection at 37uC for 1 h followed by KO7 helper phage rescue.
The rescued TG1 cells were then grown in 2xYT/carbenicillin/
kanamycin at 30uC overnight. Supernatants of the bacterial
cultures were harvested. The phagemid particles were precipitated
by PEG/NaCl from the supernatants and resuspended in PBS for
the next round of panning or phage ELISA.
Phage ELISA
Recombinant VEGF was dissolved in 0.05 M NaHCO3 buffer
pH 9.6 and immobilized at 1 mg/100 ml per well on ELISA plates
at 4uC overnight. After blocking with 5% milk in PBS to minimize
nonspecific binding, a 100 ml aliquot containing the phages to be
tested was added to each well in the ELISA plate and incubated
for 2 h at room temperature. The unbound phages were then
washed away with PBS. The phage bound to the antigen was
detected by incubation with 100 ml of HRP-conjugated anti-M13
antibody (at a 1:1000 dilution in PBS). After a brief wash with
PBS, 100 ml of ABTS (2, 29 azino-bis[3-ethylbenzthiazoline-6-
sulfonic acid]) was added before HRP activity was measured by
OD405.
Western blot
For each phage sample preparation, approximately 4610
11
phage particles were heated for 10 min in the SDS sample buffer
(2% SDS, 10% glycerol, 0.67 M Tris-HCl, pH 6.8). The
denatured phage samples were subjected to 10% SDS-PAGE.
The proteins in the SDS gel were then transferred to a PVDF
membrane. To detect HA-tagged pIII fusion proteins, the
membrane was probed first with mouse monoclonal antibody
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MPBS and then detected by anti-mouse antibody-AP conjugate
and BCIP/NBT AP substrate (Sigma).
To detect myc-tagged proteins, the membrane was probed first
with 2 mg/ml mouse monoclonal antibody 9E10 in 5% MPBS and
then detected by anti-mouse antibody-AP conjugate and the
BCIP/NBT AP substrate (Sigma).
Antibody activity and affinity measured with Biacore
The recombinant human VEGF (R&D Systems, 293-VE/CF)
was diluted to 20 mg/ml in pH 6.5 10 mM sodium acetate and
immobilized on a CM5 chip using the Amine Coupling kit (GE,
BR-1000-50) according to the manufacturer’s instructions. The
final VEGF immobilization level was approximately 300 RU. For
the thermostability study, the antibody samples were injected at
30 ml/min for a 2-min association, followed by a 5 min
dissociation at the same flow rate. The binding RUs were
recorded at 5 sec after initiation of dissociation. The surface was
regenerated by a 30-sec injection of 10 mM, pH 1.5 glycine-HCl
at 50 ml/min.
For scFv affinity measurement, the purified scFv proteins were
loaded onto a Superdex 75 size-exclusion column to remove
potential dimers and aggregates. The monomeric scFv proteins
were diluted in PBS, and scFv samples at 5 different concentra-
tions, 10 nM, 20 nM, 40 nM, 80 nM, and 160 nM, were injected
at 30 ml/min for 5 min, followed by a 10-min dissociation at the
same flow rate. The binding kinetics and affinities were
determined by globally fitting the curves of 5 concentrations to a
1:1 Langmuir model.
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